Epidemiology of anaphylaxis.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
10
2
2021
medline:
1
12
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
To understand the current global epidemiological data of anaphylaxis and identify potential strategies to improve patients' care and prevention. Anaphylaxis mortality and morbidity statistics (MMS) may gain new perspectives with the implementation of the International Classification of Diseases (ICD)-11 in the forthcoming years. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk, and support decision-making to facilitate healthcare planning and implementation of public health measures to prevent anaphylaxis. Anaphylaxis is a complex noncommunicable diseases with adverse impact on health-related quality of life of patients and their carriers and a significant proportion of deaths may be preventable. It requires an integrated holistic plan to improve quality of healthcare and gathering accurate and comparable epidemiological data is key. Morbidity related to anaphylaxis seems to be increasing worldwide whereas mortality of anaphylaxis appears to be low and stable, but this still has great challenges in capturing quality anaphylaxis MMS. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk. As knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to anaphylaxis in the ICD-11 will allow the collection of more accurate epidemiological data to support quality management of patients, and better facilitate healthcare planning to implement public health measures to prevent and reduce the morbidity and mortality attributable to these conditions.
Identifiants
pubmed: 33560740
doi: 10.1097/ACI.0000000000000722
pii: 00130832-202104000-00012
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-174Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Epidemiology is a science of high importance. Nature Communications volume 9, Article number: 1703 (2018), https://doi.org/10.1038/s41467-018-04243-3 .
World Health Organization website. Available at: https://www.who.int/topics/epidemiology/en/ [Accessed December 2018]
The Centers for Disease Control website. Available at: https://www.cdc.gov/about/history/index.html [Accessed December 2018]
Tanno LK, Bierrenbach AL, Simons FER, et al. Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy Asthma Clin Immunol 2018; 14:12.
World Health Organization website, Coronavirus disease (COVID-2019) situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports [Accessed March 2020]
Tanno LK, Casale T, Demoly P. Coronavirus Disease (COVID)-19: World Health Organization Definitions and Coding to Support the Allergy Community and Health Professionals. J Allergy Clin Immunol Pract 2020; 8:2144–2148.
Tanno LK, Demoly P, Martin B, et al. Allergy and Coronavirus Disease (COVID-19) International Survey: Real-Life Data from the Allergy Community during the Pandemic. World Allergy organization Journal 2020; In press.
World Health Organization website. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases [Accessed October 2020]
World Health Organization website. Available at: https://www.who.int/nmh/events/ncd_action_plan/en/ [Accessed October 2020]
Papadopoulos NG, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy 2012; 2:21.
Pawankar R, et al. The WAO White Book on Allergy (Update. 2013). Available at: https://www.worldallergy.org/wao-white-book-on-allergy [Accessed October 2020]
Simons FER, Ardusso LR, Bilò MB, et al. International consensus on (ICON) Anaphylaxis. World Allergy Organ J 2014; 30: 7: 9.
Panesar SS, Javad S, de Silva D, et al. on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68:1353–1361.
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in United States: an investigation into its epidemiology. Arch Intern Med 2001; 161:15–21.
Turner PJ, Campbell DE, Motouse MS, Campbell RL. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract 2020; 8:1169–1176.
Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. Clin Exp Allergy 2015; 45:1027–1039.
Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006; 117:391–397.
Muraro A, Roberts G, Worm M, et al. on behalf of EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: Guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; DOI: 10.1111/all.12437.
doi: 10.1111/all.12437
Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477–480.
Simons FER, Ardusso LRF, Bilo‘ MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4:13–37.
Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust 2006; 185:283–289.
Tanno LK, Demoly P. Anaphylaxis in Children. Pediatric Allergy and Immunol 2020; In press.
Pouessel G, Turner PJ, Worm M, et al. Food-induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clin Exp Allergy 2018; 48:1584–1593.
Tan JW, Campbell DE. Insect allergy in children. J Paediatr Child Health 2013; 49:E381–E387.
Hernandez JBR, Kim PY. Epidemiology Morbidity and Mortality. 2020 Aug 22. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31613448.
World Health Organization website. Available at: https://www.who.int/classifications/icd/en/ [Accessed October 2020]
Tanno LK, Calderon MA, Goldberg BJ, et al. Categorization of Allergic Disorders in the New World Health Organization International Classification of Diseases. Clin Transl Allergy 2014; 4:42.
Tanno LK, Ganem F, Demoly P, et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67:783–789.
Tanno LK, Simons FER, Sanchez-Borges M, et al. Joint Allergy Academies. Applying prevention concepts to anaphylaxis: a call for worldwide availability of adrenaline auto-injectors. Clin Exp Allergy 2017; 47:1108–1114.
Tanno LK, Demoly P. Joint Allergy Academies. Action plan to reach the global availability of adrenaline auto-injectors. J Investig Allergol Clin Immunol 2018.
Tanno LK, Molinari N, Bruel S, et al. Joint Allergy Academies. Field-testing the new anaphylaxis’ classification for the WHO International Classification of Diseases-11 revision. Allergy 2017; 72:820–826.
Pouessel G, Jean-Bart C, Deschildre A, et al. Food-induced anaphylaxis in infancy compared to preschool age: a retrospective analysis. Clin Exp Allergy 2020; 50:74–81.
Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014; 69:1397–1404. doi: 10.1111/all.12475. Epub 2014 Aug 16. PMID: 24989080.
doi: 10.1111/all.12475.
Cardona V, Álvarez-Perea A, Ansotegui-Zubeldia IJ, et al. Clinical practice guide for anaphylaxis in Latin America (Galaxia-Latam). Rev Alerg Mex 2019; 66: (Suppl 2): 1–39.
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082–1123.
Gloaguen A, Cesareo E, Vaux J, et al. Management of Anaphylaxis in Emergency Medicine. French Society of Emergency Medicine (SFMU) Guidelines with the Contribution of French Allergology Society (SFA) and the French Speaking Group in Pediatric Intensive Care and Emergency (GFRUP), and the support of the French pediatric pneumology and allergology society (SP2A). Ann Fr Med Urgence 2016; 6:342–364.
Tanno LK, Simons FER, Annesi-Maesano I, et al. Fatal anaphylaxis registries data support changes in the WHO anaphylaxis mortality coding rules. Orphanet Orphanet J Rare Dis 2017; 12:8.
Kase Tanno L, Demoly P. Joint Allergy Academies. Action plan to reach the global availability of adrenaline auto-injectors. J Investig Allergol Clin Immunol 2018; In press.
Tanno LK, Demoly P. One voice for anaphylaxis in France: the vision of the centre of reference in rare diseases. Rev Fr Allergol 2017; 57:583–587.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. New allergic and hypersensitivity conditions section in the international classification of diseases-11. Allergy Asthma Immunol Res 2016; 8:383–388.
Demoly P, Tanno LK, Akdis CA, et al. Global classification and coding of hypersensitivity diseases – an EAACI – WAO survey, strategic paper and review. Allergy 2014; 69:559–570.
Tanno LK, Calderon MA, Goldberg BJ, et al. Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community. Allergy 2015; 70:609–615.
Tanno LK, Calderon M, Papadopoulos NG, Demoly P. Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs. Clin Transl Allergy 2015; 5:20.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. Making allergic and hypersensitivity conditions visible in the International Classification of Diseases-11. Asian Pac Allergy 2015; 5:193–196.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. Optimization and simplification of the allergic and hypersensitivity conditions classification for the ICD-11. Allergy 2016; 71:671–676.
Tanno LK, Calderon MA, Papadopoulos NG, et al. Revisiting desensitization and allergen immunotherapy concepts for the International Classification of Diseases (ICD)-11. J Allergy Clin Immunol Pract 2016; 4:643–649.
Tanno LK, Calderon MA, Li J, et al. Updating Allergy/Hypersensitivity diagnostic procedures in the WHO ICD-11 revision. J Allergy Clin Immunol Pract 2016; 4:650–657.
Tanno LK, Calderon MA, Papadopoulos NG, et al. Joint Allergy Academies. Surveying the new allergic and hypersensitivity conditions chapter of the International classification of diseases (ICD)-11. Allergy 2016; 71:1235–1240.
Tanno LK, Calderon M, Demoly P. Joint Allergy Academies. Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11. Asia Pac Allergy 2016; 6:149–156.
Tanno LK, Calderon M, Sublett JL, et al. Joint Allergy Academies. Smoothing the transition from International Classification of Diseases, Tenth Revision, Clinical Modification to International Classification of Diseases, Eleventh Revision. J Allergy Clin Immunol Pract 2016; 4:1265–1267.
Tanno LK, Calderon MA, Smith HE, et al. Joint Allergy Academies. Dissemination of definitions and concepts of allergic and hypersensitivity conditions. World Allergy Organ J 2016; 9:24.
Tanno LK, Bierrenbach AL, Calderon MA, et al. Joint Allergy Academies. Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy 2017; 72:120–125.
Tanno LK, Ansotegui I, Demoly P. Globalization and anaphylaxis. Curr Opin Allergy Clin Immunol 2018; 18:365–369.
Tanno LK, Casale T, Papadopoulos NG, et al. A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: the example of the Joint Allergy Academies. Allergy Asthma Proc 2017; 38:54–55.
Tanno LK, Chalmers R, Bierrenbach AL, et al. on behalf Joint Allergy Academies. Changing the history of anaphylaxis mortality statistics througth the World Health Organization's International Classification of Diseases (ICD)-11. J Allergy Clin Immunol 2019; 144:627–633.
WHO website, WHO Collaborating Centres. Available at: http://apps.who.int/whocc/Detail.aspx?cc_ref=FRA-133&designation_date1=1/6/2018&designation_date2=18/7/2018& [Accessed January 2019]
World Health Organization, ICD-11 Beta Draft website. Available at: http://apps.who.int/classifications/icd11/browse/l-m/en [Accessed June 2018]
Turner PJ, Worm M, Ansotegui IJ, et al. WAO Anaphylaxis Committee. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Organ J 2019; 12:100066.
Juhn Y, Liu H. Artificial intelligence approaches using natural language processing to advance HER-based clinical research. J Allergy Clin Immunol 2020; 145:463–469.